meRfi®-GM
Escherichia coli Nissle 1917 / E. coli Nissle 1917 (EcN)
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
Contents
Escherichia coli strain Nissle 1917 (EcN) is known to reduce Food Intake / Eating and increase Energy expenditure
It is relatively safe for therapeutic applications because it does not cause colitis
The strain Escherichia coli Nissle 1917 / E. coli Nissle 1917 (EcN) is a non-pathogenic fecal bacterium, well studied as probiotic and exerts probiotic effects in humans and animals
D’Souza…
References (Sources)
- Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis
- Emerging strategies for engineering Escherichia coli Nissle 1917-based therapeutics
- Probiotic Escherichia coli Ameliorates Antibiotic-Associated Anxiety Responses in Mice
- Probiotics in prevention of antibiotic associated diarrhoea: Meta-analysis.
- Safety of probiotic Escherichia coli strain Nissle 1917 depends on intestinal microbiota and adaptive immunity of the host.
- Treatment of irritable bowel syndrome with Escherichia coli strain Nissle 1917 (EcN): A retrospective survey
- Worm-Based Alternate Assessment of Probiotic Intervention against Gut Barrier Infection